Skip to main content
77°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nanoviricides Inc
(NY:
NNVC
)
1.940
+0.040 (+2.11%)
Streaming Delayed Price
Updated: 12:54 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanoviricides Inc
< Previous
1
2
3
4
5
6
Next >
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
February 28, 2022
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended...
Via
Benzinga
27 Stocks Moving in Monday's Pre-Market Session
February 28, 2022
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) rose 45.4% to $1.00 in pre-market trading after the company reported progress on solid-state polymer battery pack development....
Via
Benzinga
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
February 15, 2022
SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...
From
NanoViricides, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
How Many Boosters Will It Take? A Global Population Beset By Pandemic Fatigue Wants A More Permanent Solution
January 31, 2022
Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts
January 19, 2022
Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. As the threat...
Via
Benzinga
NanoViricides Attempts to Leverage Decades of Combined Pharmaceutical and Biotech Experience To Bring Broad-Spectrum COVID-19 Antiviral to Market
December 20, 2021
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
NanoViricides Says Its Nanomedicine Tech Could Be the Key To Defeating Omicron and Other COVID-19 Variants
December 09, 2021
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
Exposures
COVID-19
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
November 29, 2021
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
November 16, 2021
SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...
From
NanoViricides, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment
November 15, 2021
NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized...
Via
Benzinga
Exposures
COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
November 15, 2021
Welcome back, trader! We're getting right into the thick of it this week with a look at the biggest pre-market stock movers for Monday!
Via
InvestorPlace
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
November 15, 2021
SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel...
From
NanoViricides, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate
November 15, 2021
NanoViricides Inc (NYSE: NNVC) has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. What...
Via
Benzinga
Exposures
COVID-19
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Exposures
COVID-19
Are Pfizer, Moderna, J&J Booster Shots a Panacea? This Company Says Its Broad-Spectrum Drugs to Fight COVID-19 Would Help End the Pandemic
November 02, 2021
Photo by Steven Cornfield on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Exposures
COVID-19
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
October 13, 2021
SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021...
From
NanoViricides, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
NanoViricides COVID-19 Treatment Candidate Found Effective Against Coronavirus Variants In Lab Study
October 11, 2021
Shares of NanoViricides Inc (NYSE: NNVC), a developer of antiviral therapies based on a novel nanomedicines technology, are higher Monday. What Happened: NanoViricides...
Via
Benzinga
Exposures
COVID-19
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
October 11, 2021
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure...
Via
FinancialNewsMedia
Exposures
COVID-19
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
October 11, 2021
Shelton, Connecticut -- (October 11, 2021) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral...
Via
Benzinga
Exposures
COVID-19
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
October 11, 2021
SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel...
From
NanoViricides, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
NanoViricides Leaps Forward in its Quest to Defeat COVID-19
October 05, 2021
Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19....
Via
Benzinga
Exposures
COVID-19
31 Stocks Moving In Monday's Mid-Day Session
September 27, 2021
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to...
Via
Benzinga
20 Stocks Moving in Monday's Pre-Market Session
September 27, 2021
Gainers Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) rose 49% to $3.65 in pre-market trading. Paltalk, Inc. (NASDAQ: PALT) rose 43.9% to $5.77 in pre-market...
Via
Benzinga
50 Biggest Movers From Yesterday
September 23, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement from management that the company entered into a...
Via
Benzinga
32 Stocks Moving In Wednesday's Mid-Day Session
September 22, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that the company entered into a revenue share...
Via
Benzinga
Nanoviricides Stock Surges, Nears The End Of A Pennant Pattern
September 21, 2021
Nanoviricides Inc. (NYSE:NNVC) shares are surging higher Tue...
Via
Benzinga
What Is a ‘News Pending’ Halt? What to Know as NNVC Stock Captivates Investors
September 21, 2021
Today, NanoViricides is grabbing a lot of attention due to a news pending halt that has sent NNVC stock skyrocketing.
Via
InvestorPlace
EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile
September 21, 2021
NanoViricides Inc (NYSE: NNVC) has reported significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-...
Via
Benzinga
Exposures
COVID-19
53 Biggest Movers From Yesterday
September 16, 2021
Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
38 Stocks Moving In Wednesday's Mid-Day Session
September 15, 2021
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.